Abbott Cardiovascular Systems, Inc.

Asml Netherlands B.v.

Jin Cheng

Syed F A Hossainy

Wouter Erik Roorda

Paul M Consigny

Yen-Wen Lu

Feng Chen

Christopher Feezor

Jen-Shiang Wang

Stephen R Dugan

Gordon S Stewart

Yongfa Fan

Gina Zhang

Xi Chen

Gene Park

Yu Zhao

Leiwu Zheng

Nancy Kirsten

Dianwen Zhu

Ziyang Ma

Dwight A Ambat

A drug-delivery system is provided including at least 100 &#x3bc;g of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 &#x3bc;g, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).

Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device

Growing community of inventors

San Jose, CA, United States of America

Jin Cheng